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Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin
called sickle hemoglobin (HbS). Clinical manifestations of SCD are mainly characterized by chronic hemolysis and
acute vaso-occlusive crisis, which are responsible for severe acute and chronic organ damage. SCD is widespread
in sub-Saharan Africa, in the Middle East, Indian subcontinent, and some Mediterranean regions. With voluntary
population migrations, people harboring the HbS gene have spread globally. In 2006, the World Health
Organization recognized hemoglobinopathies, including SCD, as a global public health problem and urged
national health systems worldwide to design and establish programs for the prevention and management
of SCD. Herein we describe the historical experience of the network of hemoglobinopathy centers and their
approach to SCD in Italy, a country where hemoglobinopathies have a high prevalence and where SCD,
associated with different genotypes including ß-thalassemia, is present in the native population.
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disease, Transfusion, Vaso-occlusion crisisIntroduction
The term sickle cell disease (SCD) encompasses a group
of inherited red blood cell disorders caused by a struc-
tural abnormality of hemoglobin (Hb) called sickle
hemoglobin (HbS), which originates from a single
nucleotide substitution in the gene encoding ß-globin
[1]. HbS is inherited in an autosomal recessive way and
SCD can occur due to homozygosity for HbS (HbSS), a
condition also known as sickle cell anemia (SCA), or
due to compound heterozygosity with ß-thalassemia
mutations (HbS/ß0-thalassemia and HbS/ß+-thalassemia,
previously known as microdrepanocytic disease and first© The Author(s). 2019 Open Access This artic
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other ß-globin structural variants such as HbC (HbSC
disease) [1]. HbS is functional and soluble when oxygen-
ated, but upon deoxygenation it polymerizes, leading to
the generation of misshapen red blood cells known as
sickled cells and dense erythrocytes [3]. Sickle red blood
cells show: (i) abnormal membrane mechanical stability;
(ii) increased membrane oxidation; (iii) activation of
pro-dehydrating membrane transport pathways; and (iv)
pro-adhesive molecules. The dense, rigid red blood cells
are easily trapped within organs with sluggish microcir-
culation by their interaction with the inflammatory
activated vascular endothelial cells and neutrophils.
These events generate acute vaso-occlusive events,
which leads to ischemic-reperfusion damage of target
organs such as lung, kidney or brain [3–6].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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order with high mortality and morbidity [7, 8]. The most
common acute manifestations of SCD include acute
hemolytic crisis and vaso-occlusive crisis (VOCs). VOCs
are characterized by musculoskeletal pain, which might
develop into severe form such as acute chest syndrome,
stroke or priapism [1, 3, 9–12]. In addition, with the
spleen being one of the target organs of VOC, patients
with SCD are also prone to serious bacterial infections
due to asplenism [1, 3]. The recurrent pattern of VOCs
results in chronic organ damage, which becomes clinic-
ally evident in adult patients [13]. SCD was long
regarded as a disease of children, with few surviving to
adulthood [14]. Today, thanks to advances in infection
control, vaccination and screening programs, as well as
intensive disease management, more than 95% of chil-
dren with SCD in developed countries reach adulthood
[15]. In adults with SCD, survival is estimated to be over
50 years for patients with HbSS or HbS/ß0-thalassemia
genotypes, while the survival of patients with HbSC or
HbS/ß+-thalassemia genotypes is close to that of the
general population [15].
Epidemiologic and global burden of disease studies
have shown that SCD is widespread in sub-Saharan
Africa, in the Middle East, Indian subcontinent and
some Mediterranean regions. In the last few decades,
due to voluntary population migrations, the HbS gene
has spread all over the world. A study published in 2014
estimated that the global number of migrants with HbS
increased from approximately 1.6 million in 1960, to 3.6
million in 2000 [16]. In 2006, the World Health
Organization (WHO) recognized hemoglobinopathies,
including SCD, as a global public health problem and
urged national health systems worldwide to design and
establish programs for the prevention and management
of SCD [17]. The European Union considers SCD a rare
disease.
Changes in the demographic profile of SCD have been
also reported in Italy [18–20], a country where SCD, in
particular HbS/ß-thalassemia, is historically present in
the native population. We describe here the experience
of new challenges posed to Italian health providers by
the increasing prevalence of SCD. To this purpose, we
will first discuss the changing epidemiology of SCD in
Italy, then we will briefly review the peculiarity of the
Italian treatment strategy.
Epidemiology of sickle cell disease in Italy
The prevalence of SCD throughout Italy is changing and
the presence of immigrants in the increasing number of
SCD patients in Italian regions with a historically low
disease prevalence has been documented by recent
studies [19–23]. The highest frequency of the sickle cell
allele in Italy was reported in Sicily, with an estimatedmean frequency of 2% and peaks as high as 13% [24].
Notably, in Western Sicily SCD appears to have origi-
nated from Africa, with chromosomal analysis of the
HbSS and HbS/ß-thalassemia genotypes suggesting that
the HbSS genotype found in Sicily arrived initially from
North African populations [25].
In an Italian survey of 696 cases of SCD, conducted in
the late 1990s, 518 cases (74%) were identified as com-
pound heterozygous HbS/ß-thalassemia, 149 cases (21%)
as homozygous HbSS, and 21 cases (3%) as compound
heterozygous HbS/other Hb structural variant [26]. Of
the 673 cases of SCD with a known place of residence,
60% were living in Sicily, 20% in South Italy, 6% in
Central Italy, and 13% in North Italy. Hence the survey
revealed that, in the 1990s, the majority of SCD patients
in Italy resided in Sicily and that they mostly had HbS/
ß-thalassemia. A survey update, published in 2003,
found that the proportion of SCD patients living in
North Italy had increased to 20%, but in Sicily this had
decreased to 53% [18]. Furthermore, the proportion of
patients with HbSS had increased from 21% in 1998 to
28% in 2003. A comparison of patients of non-Italian
versus Italian origin showed that non-Italian patients were
mostly homozygous for the HbS allele (72% vs 18%,
respectively), were younger (75% <18-years old vs 23%)
and lived predominantly in North Italy (61% vs 11%).
Real-life experience with the use of hydroxyurea (HU)
in SCD was assessed using data from a retrospective
Italian nationwide survey of SCD patients with heteroge-
neous descent, which registered 1,638 patients. From a
total of 652 patients who had received HU during their
disease course, 400 patients (64%) were Caucasian in
origin and 221 patients (36%) originated from Africa
[20]. It is also apparent that the genotype of the Hb
allele in Italy is changing over time with an increasing
frequency of the homozygous HbSS genotype. Screening
programs initiated in the 1970s in Italy have increased
public awareness of thalassemia and aided its prevention
in target populations as well as enabling screening for
other hemoglobinopathies [27–29]. These programs,
which aim to prevent hemoglobinopathies, have signifi-
cantly reduced the frequency of live births with SCD
[27–29]. In Sicily, an 85% decrease in the incidence of
thalassemia major and SCA (from 1 in 245 live births to
1 in 2,000) has been documented following 30 years of
preventative actions, which included legislative action, a
public awareness campaign, screening and carrier diag-
nostics, genetic counselling, and prenatal diagnosis [29].
In addition, a universal screening program for hemoglo-
binopathies, which includes voluntary pregnancy termin-
ation within the 22nd week in case of an affected fetus, is
active for couples before and/or after conception accord-
ing to the Italian law since Italy is considered an area
endemic for hemoglobinopathies [30].
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admission to an emergency department for an acute
disease-related event was assessed in a study coordinated
by the Italian Society of Thalassemia and Hemoglobin-
opathies (SITE). In total, 67 patients with SCD (48%
children, mostly with the HbSS genotype) were identi-
fied from a retrospective analysis of data collected from
2014 to 2017 [31]. The main causes of access to the
emergency department were VOC (35.8%), anemia
(19.4%), and fever (7.5%); 60% of the identified SCD
patients were then followed in reference centers for
hemoglobinopathies.
Together, these data suggest that the increased number
of patients with SCD in Italy has mostly resulted from
migratory patterns of immigrants arriving, in recent years,
from countries in which there is a high disease prevalence
and that there are approximately 2,000 patients with SCD
currently living in Italy.
Management of patients with sickle cell disease in Italy
The creation of evidence-based guidelines for SCD, as
for other uncommon or neglected diseases, has proven
challenging due to the complex clinical expression of the
disease, and the availability of clinical trials regarding
only some screening, management, and monitoring
issues of SCD. Notably, an important goal of SCD guide-
lines is to improve the awareness of SCD and increase
the number of health professionals able to provide care
for patients with SCD [32].
Effort undertaken over the past 10 years by scientific
societies involved in the care of pediatric and adult pa-
tients with SCD (the Italian Association of Hematology
and Pediatric Oncology [AIEOP] and SITE) has been to
develop guidelines for the management of children and
adults with SCD, respectively, tailoring international rec-
ommendations to the Italian health care system.
In general, currently available guidelines deal with
three main areas of SCD management: prevention of
infections, stroke, and management of acute and chronic
complications; treatment of the various complications
(VOC, pain, infections, worsening of anemia, acute chest
syndrome, vasculopathy); and specific treatment of
severe disease with disease-modifying therapies (transfu-
sion and HU) [32–37].
Preventive measures have a central position in the
management of SCD. Prophylactic antibiotics should
be initiated as early as 2 months of age in infants
and a specific vaccination program should be followed
in order to widen the protection against encapsulated
bacteria [38, 39].
Primary prevention of stroke is performed by
screening children, aged 2 to 16 years, with transcra-
nial Doppler ultrasonography; this allows the identifi-
cation of children at high risk of stroke, who areplaced on transfusions and, eventually, HU for stroke
prevention [40].
The use of chronic transfusions (typically given on a
monthly basis) to reduce the percentage of HbS in the
blood have proven effective in preventing most compli-
cations of SCD, including stroke, and in minimizing
chronic anemia with significant improvements in the
patient-centered outcome of health-related quality of life
[1, 35, 41–44]. Preliminary results from the “National
Transfusion Treatment Survey in patients with SCD”
(NCT03397017), a prospective longitudinal systemic
study designed to assess the therapeutic approach in a
large Italian cohort of patients with SCD (n=1,579), were
reported recently [19]. This national survey, which was
coordinated by SITE in collaboration with the Italian
Society of Transfusion Medicine and Immunohematol-
ogy (SIMTI) and AIEOP, showed that 14% of patients
are on regular transfusion, while 40% received both
transfusion and HU, the transfusional approach being
similar in HbSS, HbS/β°-thalassemia and HbS/β+-thalas-
semia patients, who were predominately Caucasian or
African; severe VOCs and symptomatic anemia were the
main reasons for transfusion. The rate of red blood cell
alloimmunization was comparable to the lower rate
reported in the literature [45]. Elderly Caucasian SCD
patients and their long-term follow-up represent a
unique population of SCD, and are extremely inform-
ative on aging with SCD.
The introduction of chronic transfusion in children
with cerebrovascular disease as well as the aging of
adults with SCD has increased the use of different
transfusion regimens (e.g.: simple transfusion, erythrocy-
tapheresis, red blood cell exchange), which might lead to
iron overload. The availability of iron chelators, includ-
ing deferoxamine, given parenterally, and the oral agent
deferasirox, has definitively improved clinical manage-
ment of iron-overload in SCD subjects [46–48]. Notably,
long-term iron chelation therapy with deferiprone was
associated with a similar efficacy and safety profile to
that of deferoxamine in patients with SCD and may
therefore represent an effective long-term treatment
option [49]. However, it is of note that the oral chelator
deferiprone is currently off-label.
In Italy, there is also wide experience in the treatment
of SCD with erythrocyte exchange as a means of lower-
ing HbS levels, particularly in patients who do not
tolerate or are unresponsive to HU. Indeed, manual or
automatic red blood cell exchange was shown to be safe
and effective in preventing complications of SCD for up
to 29 years, with minimal development of iron overload
and no increased risk of procedure-related complications
in both adult and pediatric SCD patients [50–52]. More
recently, an Italian double-center retrospective cross-
sectional study showed that early prophylactic
Russo et al. Orphanet Journal of Rare Diseases          (2019) 14:120 Page 4 of 9erythrocytapheresis (initiated at 10.7 ± 5.2 weeks of
gestation) improved maternal and fetal outcomes in
SCD women with a history of severe SCD-related organ
complications [53]. The generation of SITE recommen-
dations for transfusion strategies in hemoglobinopathies
has contributed to standardizing the procedures and
sharing the clinical indication to the different transfu-
sional approaches at a national level [54]. The real-life
transfusion strategy is the object of a very recent survey
[19]. A large observational study coordinated by SITE
demonstrated the efficacy of direct-acting antiviral
drugs in the eradication of hepatitis C virus (HCV) in
an Italian cohort of SCD patients infected with HCV
(n=136; 93.5% of these patients achieved a sustained
virologic response), which likely occurred due to trans-
fusion therapy prior to the introduction of blood-
donor screening in the 1990s [55].
A large body of preclinical and clinical evidence has
demonstrated that HU reduces the morbidity and mortal-
ity of both adults and children (including infants) with
SCD, with a favorable tolerability profile and without sig-
nificant short-term and long-term safety concerns [56–68].
A series of real-life reports documenting the use of HU in
Italy have recently been published [20, 22, 69]. HU was
shown to be beneficial as a treatment option in a retro-
spective, nationwide cohort study of 1,638 patients with
SCD of whom 652 patients had received HU during their
disease course [20]. Notably, only 39.8% of patients (652
out of 1,638 patients) with SCD who had attended treat-
ment centers across Italy were treated with HU, suggesting
its underutilization in clinical practice. The percentage of
HbS/β°-thalassemia and HbS/β+-thalassemia patients on
HU was even lower: 90/624 (14.4%) [19].
A sub-analysis of pediatric data from the retrospective,
nationwide cohort study [20] demonstrated the tendency
to treat children with lower doses than those recom-
mended; furthermore, although national pediatric guide-
lines recommend starting HU treatment as early as the
first months of life, this cohort of children revealed that
HU was never started before 11 months of age [22].
Nonetheless, the results of this survey highlight good ad-
herence to the Italian National Guidelines that included
detailed recommendations for the use of HU, which is
noteworthy considering patients were mainly first-
generation immigrants, who may be socially, culturally,
and economically vulnerable [22].
Since VOC are the most common acute manifestations
of SCD, the main symptom of which is severe pain, we
developed an integrated algorithm to manage acute
VOC in the emergency department (ED). In this
algorithm we introduced multimodal analgesia as an in-
novative approach to treat SCD-related pain [35, 70, 71].
Multimodal analgesia allows for a: 1) reduction of side
effects since each molecule is used at a lower dosage toobtain the same degree of analgesia of a single molecule
at a higher dosage;2) synergistic effect due to blockage
of different mechanisms of pain generation; opioid or
opioid-like actin modulates central nervous system pain
perception whereas non-steroid anti-inflammatory drugs
modulate pain of vascular origin and neuroinflammatory-
mediated pain (ischemia/reperfusion tissue injury) [70, 71].
This approach is particularly important to prevent
addiction to opioids, which is a risk of prescribing these
drugs for the treatment of VOC-related pain in SCD.
Italian guidelines for the management of children and
adults with SCD
AIEOP published comprehensive and detailed guide-
lines for the management of SCD in children in 2013
[33, 72] and, in 2014 SITE issued recommendations for
the treatment of adults with SCD [36]. These recom-
mendations have been conceived as easy-to-consult and
practice-oriented guidelines addressing the following
topics: prevention of infections and follow-up; treat-
ment of acute events (painful VOC, acute chest syn-
drome, abdominal pain with biliary dysfunction, infarct
or acute cerebrovascular events, priapism, acute anemia
and aplastic crisis); management of chronic complica-
tions (pulmonary hypertension, bone and joint compli-
cations, renal complications, and eye complications);
intensive treatment (HU and transfusion plus iron
chelation).
In addition, great care has been taken by SITE to
develop guidelines devoted to complications, such as
bone disease, which are typically observed both in adult
and pediatric SCD populations [73].
Interactive algorithm for the management of acute events
in the emergency department
SITE coordinated a panel composed of AIEOP, SIMTI,
SIMI (Italian Society of Internal Medicine), and SIMEU
(Italian Society of Emergency Medicine) and a represen-
tative of the nurses to develop an interactive, easy-to-use
algorithm for the clinical management of acute events
related to SCD in the ED (Figure 1) [35, 74]. The devel-
opment of guidelines for the triage and management of
SCD patients in the ED responds to the need to improve
awareness and knowledge of this hemoglobinopathy,
characterized by “time dependent” acute manifestations,
among health providers working in this setting where
the likelihood of encountering SCD patients will
continue to increase [35]. Timely and aggressive
interventions, like those for the management of stroke
in the general population, are strongly recommended to
prevent dramatic evolution of symptoms [35]. Evidence
shows that the management of acute VOCs in the
emergency department becomes more effective if health
providers have received training in SCD [75].
Fig. 1 Algorithm for the management of patients with sickle cell disease in the emergency department. Figure reproduced with
permission from Forni et al. 2014 [35]
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prevalence of SCD
The Italian experience in the management of SCD has
grown over the years. In contrast with other countries,
this experience has addressed not only HbSS but a num-
ber of other genotypes involving ß-thalassemia muta-
tions. Italian centers for hemoglobinopathies have cared
for patients with SCD that represent approximately 10%
of the global population with hemoglobinopathies. The
background knowledge accumulated by these centers,
and their distribution throughout Italy, highlights Italy
as an example of a successful network of expert physi-
cians on hemoglobinopathies to optimize patient clinical
management. This network has been built since the
1960s together with national programs of prevention
and screening. Due to the in- and out-migration fluxes
towards large urban centers, the distribution of patients
with SCD in regions where historically there was a low
prevalence of hemoglobinopathies makes it necessary to
widen the national network to these regions and to ex-
pand the training of specialists and of informed health
providers about this multifaceted disease. The need toreinforce the national network of hemoglobinopathy has
been addressed by AIEOP and SITE through the cre-
ation, improvement and revision of guidelines tailored to
Italy’s resources and healthcare system.
In 2017 the Italian government approved a law sup-
porting the institution of a National Thalassemias and
Hemoglobinopathies Network [76]. The main objective
of this network is to further potentiate the activity of
existing clinical centers devoted to hemoglobinopathies
and to improve access of patients to highly specialized
and comprehensive treatment. Ideally, this should
impact positively on the management of SCD in Italy.
It is generally recognized that registries are important
tools for detecting demographic patterns, allocating re-
sources, monitoring patient outcomes, and guiding deci-
sions [23, 77, 78]. The creation of an Italian national
registry of hemoglobinopathies (Registro nazionale della
talassemia e delle emoglobinopatie [National Registry of
Thalassemia and Hemoglobinopathies]) was approved in
2017 [79] due to a strong joint action of SITE and
national patients associations, and the first national
epidemiologic data should be available soon.
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programs of newborn screenings [38]. This preventive
measure may be redundant in the presence of effective
antenatal and/or prenatal screening programs, consider-
ing that specific examination for the diagnosis of hemo-
globinopathies are freely available from the National
Health Service for all child-bearing age individuals and
gynecologists screen all pregnant women who are
unaware of their status; however, newborn screening
becomes crucial for individuals from high-risk ethnic
groups who may be unaware of their carrier status as
they were never screened for SCD in their country of
origin or if there are situations of segregation that cause
pregnancy to be outside of the normal care channels. To
date, published evidence concerning newborn screening
for SCD in Italy is limited to a few regional pilot projects
[30, 80–83]. A scientific discussion has been opened by
a recent Pan-European consensus conference on new-
born screening for SCD, which involved a panel of >50
SCD experts from 13 European countries, and has
recently been published [84]. Finally, recent evidence
from a retrospective study highlights the importance of
SCD screening of refugees, from countries with a high
frequency of HbS, on their arrival in Italy [31].
Research activities carried out over the last 10 years in
Italy
Beside the organization of care for patients with SCD,
efforts have been made to develop research programs
and involve researchers in SCD both in preclinical and
clinical studies. This effort was directed on the following
topics: genetic aspects of the disease, and its possible
reciprocal influence with other genes [85]; mechanisms
related to the molecular pathophysiology of the disease
[5, 86–94]; prenatal diagnosis, exploring either methods
or clinical impact [29, 95]; iron monitoring [49]; chronic
organ damage monitoring, either liver [96, 97], kidney
[98], heart [99] or brain [100–103]; cognitive function
[104, 105].
Conclusions and perspectives
Overall, the Italian historical experience regarding the
global care of hemoglobinopathies is an example of
adherence to the recommendations of the WHO to im-
plement comprehensive national programs for the pre-
vention and management of SCD. Alongside this is the
institution of the National Thalassemias and Hemoglo-
binopathies Network [76], which is designed to further
potentiate the activity of existing clinical centers devoted
to hemoglobinopathies, to improve access of patients to
highly specialized and comprehensive treatment in Italy,
and to improve the coordination of initiatives and access
to new therapeutical approaches. In support of this
activity, a number of easy-to-use, practice-oriented anddetailed recommendations have been developed by
National Scientific Societies. These will no doubt in-
crease the awareness and understanding of SCD among
Italian clinicians and further optimize the management
of this complex and severe condition. These are ambi-
tious, but feasible, goals and further effort will be
required from all professionals involved in the manage-
ment of SCD. It is possible that the availability of novel
drug therapies (crizanlizumab, voxelotor, l-glutamine),
bone marrow transplant alternatives from the typical fa-
miliar donor (haploidentical, matched unrelated donor),
and gene therapy may change the clinical outcome of
SCD. As such, a sound national network can facilitate
the access of patients to the most appropriate treatment.
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